Abstracts - faqs.org

Abstracts

Biological sciences

Search abstracts:
Abstracts » Biological sciences

Familial porphyria cutanea tarda: characterization of seven novel uroporphyrinogen decarboxylase mutations and frequency of common hemochromatosis alleles

Article Abstract:

Familial porphyria cutanea tarda (f-PCT), which comes from half-normal activity of uroporphyrinogen decarboxylase (URO-D) and is autosomal dominant, is discussed with information on frequency of common hemochromatosis alleles and characterization of seven novel uroporphyrinogen decarboxylase mutations. No correlation between f-PCT disease severity and the URO-D and/or hemochromatosis genotypes is clearly established, and marked genetic heterogeneity underlies f-PCT.

Author: Desnick, Robert J., Mendez, Manuel, Sorkin, Lonnie, Rossetti, Maria Victora, Astrin, Kenneth H., Batlle, Alcira M. del C., Parera, Victoria E., Aizencang, Gerardo
Publisher: University of Chicago Press
Publication Name: American Journal of Human Genetics
Subject: Biological sciences
ISSN: 0002-9297
Year: 1998
Argentina, Statistical Data Included, Usage, Abnormalities, Physiological aspects, Hepatitis C, Liver, Enzymes, Skin, Chromosome mapping, Genetic disorders, Genetic counseling, Skin abnormalities

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


ALAD porphyria is a conformational disease

Article Abstract:

ALAD porphyria is a rare porphyric disorder caused by a profound lack of porphobilinogen synthase (PBGS) activity. Study is conducted to demonstrate that each porphyria-associated mutation shifts the human PBGS morpheein equilibrium toward the hexamer which provides a new way to think about genetic alterations that compromise function but not at the enzyme active site.

Author: Jaffe, Eileen K., Stith, Linda
Publisher: University of Chicago Press
Publication Name: American Journal of Human Genetics
Subject: Biological sciences
ISSN: 0002-9297
Year: 2007
Binding sites (Biochemistry), Active sites (Biochemistry)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells

Article Abstract:

The feasibility of gene therapy in congenital erthropoietic porphyria (CEP) is tested using a murine model. It is demonstrated that transplantation of genetically modified hematpoietic stem cells at a moderate transproduction level supports the proof of concept of a gene therapy in CEP.

Author: Robert-Richard, Elodie, Moreau-Gaudry, Francois, Lalanne, Magalie, Lamrissi-Garcia, Isabelle, Cario-Andre, Muriel, Guyonnet-Duperat, Veronique, Taine, Laurence, Ged, Cecile, Verneuil, Hubert de
Publisher: University of Chicago Press
Publication Name: American Journal of Human Genetics
Subject: Biological sciences
ISSN: 0002-9297
Year: 2008
Genetically modified mice, Animal genetic engineering

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Research, United States, Genetic aspects, Porphyria, Causes of
Similar abstracts:
  • Abstracts: Isolation and characterization of mutations causing abnormal eversion of the vulva in Caenorhabditis elegans
  • Abstracts: Characterization of the dopa decarboxylase gene of manduca sexta and its suppression by 20-hydroxyecdysone. Border of Notch activity establishes a boundary between the two dorsal appendage tube cell types
  • Abstracts: Effect of p75NTR on the regulation of naturally occurring cell death and retinal ganglion cell number in the mouse eye
  • Abstracts: Identification and characterization of homeobox transcription factor genes in strongylocentrotus purpuratus, and their expression in embryonic development
  • Abstracts: Immunochemical characterization of temperature-regulated production of enterocin L50 (EntL50A and EntL50B), enterocin P, and enterocin Q by Enterococcus faecium L50. part 2
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.